Abstract: A method includes providing, by a server computer, a shared workspace for facilitating collaborative work by a plurality of users with respect to a plurality of shared-access objects; obtaining real-time activity information describing ongoing actions currently being performed with respect to one or more of the shared-access objects; determining, based at least in part on the real-time activity information, whether a real-time notification rule is satisfied; outputting, for display in an activity stream and in response to determining that the real-time notification rule is satisfied, a real-time notification; and removing, from display in the activity stream, the real-time notification upon determining that the real-time notification rule is no longer satisfied.

Abstract: A method includes receiving, at one or more server computers, an activity information request regarding an object; determining whether a user associated with the activity information request is currently authorized to access the object or was previously authorized to access the object; if the user is currently authorized to access the object, permitting unrestricted access to a plurality of activity information items describing actions associated with the object; and if the user was previously authorized to access the object, permitting access to a filtered set of activity information items based on the plurality of activity information items.

Abstract: The present invention is directed to clock domain conflict analysis of a timing graph that features, dissociating clock domains of one or more of a path having conflicting clock domains while preserving the original clock domain relationship of the edges in the path. To that end, the method includes generating a timing graph having a source instance, a destination instance and a plurality of edges defining a plurality of signal paths between the source instance and the destination instance. A plurality of clock domains is corresponded to the timing graph, with a subset of the plurality of edges being associated with more than one clock domain. From the subset, conflicting clock domains associated with a common edge are identified. In response to identification of the conflict, one of the clock domains is dissociated from one of the edges of the subset.

Abstract: The present invention relates to compounds of Formula I or a stereomer, a tautomer, a solvate, a pharmaceutically acceptable salt, or a prodrug thereof, pharmaceutical formulations containing the compounds, methods of treatments using the compounds, for example, protein tyrosine kinase-associated disorders such as immunologic and oncologic disorders and methods of preparing medicaments comprising the compounds.

Abstract: The present invention comprises a new class of compounds useful for the prophylaxis and treatment of protein kinase mediated diseases, including inflammation, cancer and related conditions. The compounds have a general Formula I wherein A1, A2, A3, B, R1, R2, R3 and R4 are defined herein. Accordingly, the invention also comprises pharmaceutical compositions comprising the compounds of the invention, methods for the prophylaxis and treatment of kinase mediated diseases using the compounds and compositions of the invention, and intermediates and processes useful for the preparation of compounds of the invention.

Abstract: Selected compounds are effective for prophylaxis and treatment of diseases, such as HGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

Abstract: The present invention relates to furanopyrimidine compounds having the general Formula I: and stereoisomers, tautomers, solvates, pharmaceutically acceptable salts and derivatives, and prodrugs thereof. The invention also includes pharmaceutical compositions comprising a compound of Formula I, methods of treating various diseases and conditions in a mammal, including inflammation, inhibition of T cell activation, proliferation, arthritis, organ transplant, ischemic or reperfusion injury, myocardial infarction, stroke, multiple sclerosis, inflammatory bowel disease, Crohn's disease, lupus, hypersensitivity, type 1 diabetes, psoriasis, dermatitis, Hashimoto's thyroiditis, Sjogren's syndrome, autoimmune hyperthyroidism, Addison's disease, autoimmune diseases, glomerulonephritis, allergic diseases, asthma, hayfever, eczema, cancer, colon carcinoma and thymoma, comprising administering to the mammal a therapeutically effective amount of a compound of Formula I.